179 related articles for article (PubMed ID: 15038390)
1. Dystrophin expression in myofibers of Duchenne muscular dystrophy patients following intramuscular injections of normal myogenic cells.
Skuk D; Roy B; Goulet M; Chapdelaine P; Bouchard JP; Roy R; Dugré FJ; Lachance JG; Deschênes L; Hélène S; Sylvain M; Tremblay JP
Mol Ther; 2004 Mar; 9(3):475-82. PubMed ID: 15038390
[TBL] [Abstract][Full Text] [Related]
2. Dystrophin expression in muscles of duchenne muscular dystrophy patients after high-density injections of normal myogenic cells.
Skuk D; Goulet M; Roy B; Chapdelaine P; Bouchard JP; Roy R; Dugré FJ; Sylvain M; Lachance JG; Deschênes L; Senay H; Tremblay JP
J Neuropathol Exp Neurol; 2006 Apr; 65(4):371-86. PubMed ID: 16691118
[TBL] [Abstract][Full Text] [Related]
3. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study.
Kinali M; Arechavala-Gomeza V; Feng L; Cirak S; Hunt D; Adkin C; Guglieri M; Ashton E; Abbs S; Nihoyannopoulos P; Garralda ME; Rutherford M; McCulley C; Popplewell L; Graham IR; Dickson G; Wood MJ; Wells DJ; Wilton SD; Kole R; Straub V; Bushby K; Sewry C; Morgan JE; Muntoni F
Lancet Neurol; 2009 Oct; 8(10):918-28. PubMed ID: 19713152
[TBL] [Abstract][Full Text] [Related]
4. First test of a "high-density injection" protocol for myogenic cell transplantation throughout large volumes of muscles in a Duchenne muscular dystrophy patient: eighteen months follow-up.
Skuk D; Goulet M; Roy B; Piette V; Côté CH; Chapdelaine P; Hogrel JY; Paradis M; Bouchard JP; Sylvain M; Lachance JG; Tremblay JP
Neuromuscul Disord; 2007 Jan; 17(1):38-46. PubMed ID: 17142039
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of dystrophin plasmid-based gene therapy in Duchenne/Becker muscular dystrophy.
Romero NB; Braun S; Benveniste O; Leturcq F; Hogrel JY; Morris GE; Barois A; Eymard B; Payan C; Ortega V; Boch AL; Lejean L; Thioudellet C; Mourot B; Escot C; Choquel A; Recan D; Kaplan JC; Dickson G; Klatzmann D; Molinier-Frenckel V; Guillet JG; Squiban P; Herson S; Fardeau M
Hum Gene Ther; 2004 Nov; 15(11):1065-76. PubMed ID: 15610607
[TBL] [Abstract][Full Text] [Related]
6. Chimeric RNA/ethylene-bridged nucleic acids promote dystrophin expression in myocytes of duchenne muscular dystrophy by inducing skipping of the nonsense mutation-encoding exon.
Surono A; Van Khanh T; Takeshima Y; Wada H; Yagi M; Takagi M; Koizumi M; Matsuo M
Hum Gene Ther; 2004 Aug; 15(8):749-57. PubMed ID: 15319032
[TBL] [Abstract][Full Text] [Related]
7. Proteasome inhibitor (MG-132) treatment of mdx mice rescues the expression and membrane localization of dystrophin and dystrophin-associated proteins.
Bonuccelli G; Sotgia F; Schubert W; Park DS; Frank PG; Woodman SE; Insabato L; Cammer M; Minetti C; Lisanti MP
Am J Pathol; 2003 Oct; 163(4):1663-75. PubMed ID: 14507673
[TBL] [Abstract][Full Text] [Related]
8. Functional efficacy of dystrophin expression from plasmids delivered to mdx mice by hydrodynamic limb vein injection.
Zhang G; Wooddell CI; Hegge JO; Griffin JB; Huss T; Braun S; Wolff JA
Hum Gene Ther; 2010 Feb; 21(2):221-37. PubMed ID: 19788386
[TBL] [Abstract][Full Text] [Related]
9. Intravenous infusion of an antisense oligonucleotide results in exon skipping in muscle dystrophin mRNA of Duchenne muscular dystrophy.
Takeshima Y; Yagi M; Wada H; Ishibashi K; Nishiyama A; Kakumoto M; Sakaeda T; Saura R; Okumura K; Matsuo M
Pediatr Res; 2006 May; 59(5):690-4. PubMed ID: 16627883
[TBL] [Abstract][Full Text] [Related]
10. Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells.
van Deutekom JC; Bremmer-Bout M; Janson AA; Ginjaar IB; Baas F; den Dunnen JT; van Ommen GJ
Hum Mol Genet; 2001 Jul; 10(15):1547-54. PubMed ID: 11468272
[TBL] [Abstract][Full Text] [Related]
11. Oligonucleotides against a splicing enhancer sequence led to dystrophin production in muscle cells from a Duchenne muscular dystrophy patient.
Takeshima Y; Wada H; Yagi M; Ishikawa Y; Ishikawa Y; Minami R; Nakamura H; Matsuo M
Brain Dev; 2001 Dec; 23(8):788-90. PubMed ID: 11720794
[No Abstract] [Full Text] [Related]
12. Transduction of full-length dystrophin to multiple skeletal muscles improves motor performance and life span in utrophin/dystrophin double knockout mice.
Kawano R; Ishizaki M; Maeda Y; Uchida Y; Kimura E; Uchino M
Mol Ther; 2008 May; 16(5):825-31. PubMed ID: 18334987
[TBL] [Abstract][Full Text] [Related]
13. Immortalized skin fibroblasts expressing conditional MyoD as a renewable and reliable source of converted human muscle cells to assess therapeutic strategies for muscular dystrophies: validation of an exon-skipping approach to restore dystrophin in Duchenne muscular dystrophy cells.
Chaouch S; Mouly V; Goyenvalle A; Vulin A; Mamchaoui K; Negroni E; Di Santo J; Butler-Browne G; Torrente Y; Garcia L; Furling D
Hum Gene Ther; 2009 Jul; 20(7):784-90. PubMed ID: 19358679
[TBL] [Abstract][Full Text] [Related]
14. Long-term persistence of donor nuclei in a Duchenne muscular dystrophy patient receiving bone marrow transplantation.
Gussoni E; Bennett RR; Muskiewicz KR; Meyerrose T; Nolta JA; Gilgoff I; Stein J; Chan YM; Lidov HG; Bönnemann CG; Von Moers A; Morris GE; Den Dunnen JT; Chamberlain JS; Kunkel LM; Weinberg K
J Clin Invest; 2002 Sep; 110(6):807-14. PubMed ID: 12235112
[TBL] [Abstract][Full Text] [Related]
15. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.
Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T
Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998
[TBL] [Abstract][Full Text] [Related]
16. Electron microscopic observations of triple immunogold labelling for dystrophin, beta-dystroglycan and adhalin in human skeletal myofibers.
Inoue M; Wakayama Y; Murahashi M; Shibuya S; Jimi T; Kojima H; Oniki H
Acta Neuropathol; 1996 Dec; 92(6):569-75. PubMed ID: 8960314
[TBL] [Abstract][Full Text] [Related]
17. Dystrophic phenotype of canine X-linked muscular dystrophy is mitigated by adenovirus-mediated utrophin gene transfer.
Cerletti M; Negri T; Cozzi F; Colpo R; Andreetta F; Croci D; Davies KE; Cornelio F; Pozza O; Karpati G; Gilbert R; Mora M
Gene Ther; 2003 May; 10(9):750-7. PubMed ID: 12704413
[TBL] [Abstract][Full Text] [Related]
18. Aciculin and its relation to dystrophin: immunocytochemical studies in human normal and Duchenne dystrophy quadriceps muscles.
Wakayama Y; Inoue M; Kojima H; Murahashi M; Shibuya S; Yamashita S; Oniki H
Acta Neuropathol; 2000 Jun; 99(6):654-62. PubMed ID: 10867799
[TBL] [Abstract][Full Text] [Related]
19. Intraarterial delivery of naked plasmid DNA expressing full-length mouse dystrophin in the mdx mouse model of duchenne muscular dystrophy.
Zhang G; Ludtke JJ; Thioudellet C; Kleinpeter P; Antoniou M; Herweijer H; Braun S; Wolff JA
Hum Gene Ther; 2004 Aug; 15(8):770-82. PubMed ID: 15319034
[TBL] [Abstract][Full Text] [Related]
20. A highly functional mini-dystrophin/GFP fusion gene for cell and gene therapy studies of Duchenne muscular dystrophy.
Li S; Kimura E; Ng R; Fall BM; Meuse L; Reyes M; Faulkner JA; Chamberlain JS
Hum Mol Genet; 2006 May; 15(10):1610-22. PubMed ID: 16595609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
